Pfizer will be providing 50 percent of the support needed to launch a performance-improvement CME research initiative that will look at how well current CME assessment methods work when it comes to shaping ongoing diabetes care. That announcement was made in early May by the Joslin Diabetes Center, an affiliate of Harvard Medical School, which will launch the initiative. (Pfizer’s main product lines do not encompass the diabetes therapeutic area.) Pfizer’s chief medical officer, Freda ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to Pfizer to Support Joslin PI CME Research Initiative, you'll get exclusive access to a large archive of premium content.

Already registered? here.